Trial Profile
Effect of Telaprevir in triple therapy for chronic hepatitis C patients on Intrahepatic immunological Mechanisms
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ETIM
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2013 Planned end date changed from 1 Apr 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.